BAKER BROS. ADVISORS LP
Q4 2023 13F-HR Holdings
Net value change ($000)
-8,562,436
(-49.3%)
New positions
5
Sold out positions
22
Turnover %
116.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ACAD | 448,792 | 50.2% |
| MDGL | 230,124 | 102.0% |
| INCY | 181,651 | 8.7% |
| Mirati Therapeutics, Inc. | 180,725 | 294.3% |
| RYTM | 140,482 | 91.4% |
| KYMR | 86,625 | 131.2% |
| RVMD | 73,162 | 98.2% |
| Cerevel Therapeutics Holdings, Inc. | 67,840 | NEW |
| IMCR | 41,390 | 31.6% |
| ABCL | 35,304 | 37.0% |
Top Reduces (Value $000, Stocks/ETFs)
| Seagen Inc. | -9,452,165 | -100.0% |
| BMRN | -337,131 | -100.0% |
| ONC | -192,679 | -9.2% |
| SpringWorks Therapeutics, Inc. | -69,356 | -100.0% |
| AKRO | -64,491 | -53.8% |
| ROIV | -53,455 | -38.5% |
| BCRX | -29,337 | -32.6% |
| CABA | -23,958 | -98.8% |
| ARGX | -16,815 | -22.6% |
| COGT | -12,606 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|